Hydrochloride Salt of the GABAkine KRM-II-81

Imidazodiazepine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-alpha][1,4]diazepin-3-yl) oxazole or KRM-II-81) is a potentiator of GABAA receptors (a GABAkine) undergoing preparation for clinical development. KRM-II-81 is active against many seizure and pain models in rodents, where it exhibits improved pharmacological properties over standard-of-care agents. Since salts can be utilized to create opportunities for increased solubility, enhanced absorption, and distribution, as well as for efficient methods of bulk synthesis, a hydrochloride salt of KRM-II-81 was prepared. KRM-II-81 center dot HCl was produced from the free base with anhydrous hydrochloric acid. The formation of the monohydrochloride salt was confirmed by X-ray crystallography, as well as H-1 NMR and C-13 NMR analyses. High water solubility and a lower partition coefficient (octanol/water) were exhibited by KRM-II-81 center dot HCl as compared to the free base. Oral administration of either KRM-II-81 center dot HCl or the free base resulted in high concentrations in the brain and plasma of rats. Oral dosing in mice significantly increased the latency to both clonic and tonic convulsions and decreased pentylenetetrazol-induced lethality. The increased water solubility of the HCl salt enables intravenous dosing and the potential for higher concentration formulations compared with the free base without impacting anticonvulsant potency. Thus, KRM-II-81 & BULL;HCl adds an important new compound to facilitate the development of these imidazodiazepines for clinical evaluation.

Automated summary

KRM-II-81 is an active compound with improved pharmacological properties for seizure and pain models in rodents. Its hydrochloride salt exhibits higher water solubility and lower partition coefficient compared to the free base. Oral administration or intravenous dosing of KRM-II-81 results in high concentrations in the brain and plasma, leading to increased anticonvulsant potency.